<DOC>
	<DOCNO>NCT00591851</DOCNO>
	<brief_summary>HER-2/neu ( + ) breast cancer aggressive form breast cancer . HER-2/neu protein overproduce tumor . It make cancer aggressive . Standard treatment type cancer help people , moderate high chance cancer may come back . The purpose study see new regimen effective prevent cancer come back . This phase II trial . In trial , patient get drug regimen test small group people see dose safe . Researchers wish see effective drug HER-2/neu ( + ) breast cancer . The objective include look short-term side effect risks drug . All drug regimen affect heart serious side effect . The drug affect heart function primary focus .</brief_summary>
	<brief_title>Phase II Study Dose-Dense Doxurubicin Cyclophosphamide ( AC ) Followed By Paclitaxel With Trastuzumab HER2/ NEU-Amplified Breast Cancer : Feasibility</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adenocarcinoma breast cancer ECOG performance status 0 1 peripheral neuropathy less equal 1 discontinue hormonal therapy chemoprevention onstudy LVEF MUGA &gt; 55 % ? Absolute neutrophil count ( ANC ) &gt; 1000/µL ) platelet count &gt; 100,000/µL ) SGOT OR SGPT &lt; 92.5 units/L Stage IV breast cancer chemotherapy , radiation therapy , immunotherapy , biotherapy CURRENT breast cancer pregnant lactate patient active second malignancy , adequately treat nonmelanoma skin cancer situ cervical cancer previous allergy/hypersensitivity Doxorubicin , Cyclophosphamide , Paclitaxel , drug formulate Cremophor EL ? unstable angina , congestive heart failure , current use digitalis , betablockers , calcium blocker therapy congestive heart failure , arrhythmia require medical therapy , history myocardial infarction within 12 month psychiatric illness prevents understanding nature study comply protocol requirement ? active , unresolved infection sensitivity E. coli derive protein prior chemotherapy anthracycline prior Herceptin therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adenocarcinoma breast</keyword>
	<keyword>cardiac safety</keyword>
	<keyword>Breast cancer patient see Memorial Sloan-Kettering Cancer Center</keyword>
</DOC>